Literature DB >> 11086059

APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.

T L Warren1, S K Bhatia, A M Acosta, C E Dahle, T L Ratliff, A M Krieg, G J Weiner.   

Abstract

Oligonucleotides containing unmethylated CpG motifs (cytosine-phosphorothioate-guanine oligodeoxynucleotide (CpG ODN)) are potent immunostimulatory agents capable of enhancing the Ag-specific Th1 response when used as immune adjuvants. We evaluated the cellular mechanisms responsible for this effect. Development of a CTL response was enhanced when mice were immunized with peptide-pulsed dendritic cells (DCs) treated with CpG ODN. However, in vitro, CpG ODN had no direct effect on highly purified T cells. In vitro, CpG ODN treatment of peptide- or protein-pulsed DCs enhanced the ability of the DCs to activate class I-restricted T cells. The presence of helper T cells enhanced this effect, indicating that treatment with CpG ODN does not obviate the role of T cell help. The enhanced ability of CpG ODN-treated DCs to activate T cells was present but blunted when DCs derived from IL-12 knockout mice were used. Fixation of Ag-pulsed, CpG ODN-treated DCs limited their ability to activate T cells. In contrast, fixation had little effect on DC activation of T cells when DCs were not exposed to CpG ODN. This indicates that production of soluble factors by DCs stimulated with CpG ODN plays a particularly important role in their ability to activate class I-restricted T cells. We conclude that CpG ODN enhances the development of a cellular immune response by stimulating APCs such as DCs, to produce IL-12 and other soluble factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086059     DOI: 10.4049/jimmunol.165.11.6244

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

Review 2.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 3.  The role of innate immune-stimulated epithelial apoptosis during gastrointestinal inflammatory diseases.

Authors:  Richard H Siggers; David J Hackam
Journal:  Cell Mol Life Sci       Date:  2011-10-11       Impact factor: 9.261

Review 4.  Innovative strategies for co-delivering antigens and CpG oligonucleotides.

Authors:  Yogita Krishnamachari; Aliasger K Salem
Journal:  Adv Drug Deliv Rev       Date:  2009-01-19       Impact factor: 15.470

5.  Bone marrow-derived dendritic cells pulsed with tumor lysates induce anti-tumor immunity against gastric cancer ex vivo.

Authors:  Yan-Lin Li; Yu-Gang Wu; Yong-Qing Wang; Zhong Li; Rong-Chao Wang; Liang Wang; Yan-Yun Zhang
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

6.  CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model.

Authors:  Tai-Gyu Kim; Chang-Hyun Kim; Eun Ha Won; Su Mi Bae; Woong-Shick Ahn; Jae-Bok Park; Jeong-Im Sin
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

7.  Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.

Authors:  Emmanuel T Akporiaye; Deborah Bradley-Dunlop; Sandra J Gendler; Pinku Mukherjee; Cathy S Madsen; Tobias Hahn; David G Besselsen; Sharon M Dial; Haiyan Cui; Katrina Trevor
Journal:  Vaccine       Date:  2007-07-24       Impact factor: 3.641

8.  CXCL10 is critical for the generation of protective CD8 T cell response induced by antigen pulsed CpG-ODN activated dendritic cells.

Authors:  Saikat Majumder; Surajit Bhattacharjee; Bidisha Paul Chowdhury; Subrata Majumdar
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

9.  Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.

Authors:  S M Geary; C D Lemke; D M Lubaroff; A K Salem
Journal:  Cancer Immunol Immunother       Date:  2011-05-28       Impact factor: 6.630

10.  Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues.

Authors:  J Rodrigo Mora; Guiying Cheng; Dominic Picarella; Michael Briskin; Natasha Buchanan; Ulrich H von Andrian
Journal:  J Exp Med       Date:  2005-01-10       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.